Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Goodwill (2019 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Goodwill for 7 consecutive years, with $17.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Goodwill changed N/A year-over-year to $17.4 million, compared with a TTM value of $17.4 million through Sep 2025, changed N/A, and an annual FY2024 reading of $17.4 million, changed 0.0% over the prior year.
  • Goodwill was $17.4 million for Q3 2025 at X4 Pharmaceuticals, roughly flat from $17.4 million in the prior quarter.
  • Across five years, Goodwill topped out at $27.1 million in Q1 2021 and bottomed at $17.4 million in Q4 2021.
  • Average Goodwill over 5 years is $19.2 million, with a median of $17.4 million recorded in 2021.
  • Peak annual rise in Goodwill hit 0.0% in 2021, while the deepest fall reached 36.0% in 2021.
  • Year by year, Goodwill stood at $17.4 million in 2021, then changed by 0.0% to $17.4 million in 2022, then changed by 0.0% to $17.4 million in 2023, then changed by 0.0% to $17.4 million in 2024, then changed by 0.0% to $17.4 million in 2025.
  • Business Quant data shows Goodwill for XFOR at $17.4 million in Q3 2025, $17.4 million in Q2 2025, and $17.4 million in Q4 2024.